These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38971641)

  • 1. Correlating Predicted Adjuvant Therapy Benefit and Risk of Recurrence Between Breast Cancer Index (BCI) and the 21-Gene Oncotype DX Recurrence Score (RS).
    Casasanta N; Patel R; Raymond S; Kier MW; Blanter J; Sohval S; Hovstadius M; Wu C; Zimmerman B; Cascetta K; Bagiella E; Tiersten A
    Clin Breast Cancer; 2024 Oct; 24(7):585-596. PubMed ID: 38971641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31.
    Berger NF; Zimmerman BS; Tharakan S; Suchman K; Cascetta KP; Blanter J; Moshier E; Ru M; Jaffer S; Tiersten A
    Oncology; 2021; 99(11):699-702. PubMed ID: 34425579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
    Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
    Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
    Sgroi DC; Sestak I; Cuzick J; Zhang Y; Schnabel CA; Schroeder B; Erlander MG; Dunbier A; Sidhu K; Lopez-Knowles E; Goss PE; Dowsett M
    Lancet Oncol; 2013 Oct; 14(11):1067-1076. PubMed ID: 24035531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
    Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
    Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.
    Bartlett JMS; Sgroi DC; Treuner K; Zhang Y; Ahmed I; Piper T; Salunga R; Brachtel EF; Pirrie SJ; Schnabel CA; Rea DW
    Ann Oncol; 2019 Nov; 30(11):1776-1783. PubMed ID: 31504126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
    Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D
    Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is Age Trumping Genetic Profiling in Clinical Practice? Relationship of Chemotherapy Recommendation and Oncotype DX Recurrence Score in Patients Aged < 50 Years versus ≥ 50 Years, and Trends Over Time.
    Williams AD; Reyes SA; Arlow RL; Tchou J; De La Cruz LM
    Ann Surg Oncol; 2018 Oct; 25(10):2875-2883. PubMed ID: 29959613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
    Dodson A; Okonji D; Assersohn L; Rigg A; Sheri A; Turner N; Smith I; Parton M; Dowsett M
    Breast Cancer Res Treat; 2018 Feb; 168(1):249-258. PubMed ID: 29128896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
    Glasgow A; Sechrist H; Bomeisl P; Gilmore H; Harbhajanka A
    Breast Cancer; 2021 Mar; 28(2):321-328. PubMed ID: 32951186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer.
    Sestak I; Zhang Y; Schroeder BE; Schnabel CA; Dowsett M; Cuzick J; Sgroi D
    Clin Cancer Res; 2016 Oct; 22(20):5043-5048. PubMed ID: 27252417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A preliminary report of head-to-head comparison of 18-gene-based clinical-genomic model and oncotype DX 21-gene assay for predicting recurrence of early-stage breast cancer.
    Yang PS; Lee YH; Chung CF; Chang YC; Wang MY; Lo C; Tsai LW; Shih KH; Lei J; Yu BL; Cheng SH; Huang CS
    Jpn J Clin Oncol; 2019 Dec; 49(11):1029-1036. PubMed ID: 31287883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.
    Zhang L; Hsieh MC; Petkov V; Yu Q; Chiu YW; Wu XC
    Breast Cancer Res Treat; 2020 Apr; 180(2):491-501. PubMed ID: 32060781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of Oncotype DX recurrence score using deep multi-layer perceptrons in estrogen receptor-positive, HER2-negative breast cancer.
    Baltres A; Al Masry Z; Zemouri R; Valmary-Degano S; Arnould L; Zerhouni N; Devalland C
    Breast Cancer; 2020 Sep; 27(5):1007-1016. PubMed ID: 32385567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of Ki-67 proliferative index with oncotype DX recurrence score in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer with low-burden axillary nodal disease - a review of 137 cases.
    Saad Abdalla Al-Zawi A; Anichkina KA; Elamass M; Aladili Z
    Pol J Pathol; 2024; 75(1):8-18. PubMed ID: 38741425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a nomogram to predict recurrence scores obtained using Oncotype DX in Japanese patients with breast cancer.
    Shibata A; Tamura N; Kinowaki K; Nishikawa A; Tanaka K; Kobayashi Y; Ogura T; Tanabe Y; Kawabata H
    Breast Cancer; 2024 Nov; 31(6):1018-1027. PubMed ID: 39020239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.
    Carlson JJ; Roth JA
    Breast Cancer Res Treat; 2013 Aug; 141(1):13-22. PubMed ID: 23974828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer.
    Lee SB; Kim J; Sohn G; Kim J; Chung IY; Kim HJ; Ko BS; Son BH; Ahn SH; Lee JW; Jung KH
    Cancer Res Treat; 2019 Jul; 51(3):1073-1085. PubMed ID: 30384581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of Oncotype Dx score with tumor grade, size, nodal status, proliferative marker Ki67 and Nottingham Prognostic Index in early breast cancer tumors in Saudi Population.
    Durrani S; Al-Mushawa F; Heena H; Wani T; Al-Qahtani A
    Ann Diagn Pathol; 2021 Apr; 51():151674. PubMed ID: 33360027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
    Fayaz S; Eissa HE; Demian GA
    J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.